ArticlePharmacoEconomics2022

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Timothy Spelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.